[{"id":"a5794ed7-ec20-4c8e-af55-9e059e2c03e3","acronym":"RASolute 302","url":"https://clinicaltrials.gov/study/NCT06625320","created_at":"2025-02-25T14:19:38.953Z","updated_at":"2025-02-25T14:19:38.953Z","phase":"Phase 3","brief_title":"Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","source_id_and_acronym":"NCT06625320 - RASolute 302","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" RAS","pipe":" | ","alterations":" RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • daraxonrasib (RMC-6236)"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 10/16/2024","start_date":" 10/16/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-17"},{"id":"e5cc79e0-1971-4c9b-a64f-b981c73e5ffd","acronym":"BREAKER-101","url":"https://clinicaltrials.gov/study/NCT06625775","created_at":"2025-02-25T18:45:57.991Z","updated_at":"2025-02-25T18:45:57.991Z","phase":"Phase 1","brief_title":"Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)","source_id_and_acronym":"NCT06625775 - BREAKER-101","lead_sponsor":"TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 10/29/2024","start_date":" 10/29/2024","primary_txt":" Primary completion: 11/01/2028","primary_completion_date":" 11/01/2028","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2025-01-24"},{"id":"dc418061-81ed-44f9-ba51-9700e1510d92","acronym":"","url":"https://clinicaltrials.gov/study/NCT06128551","created_at":"2023-11-13T16:14:48.821Z","updated_at":"2024-07-02T16:34:25.613Z","phase":"Phase 1","brief_title":"Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors","source_id_and_acronym":"NCT06128551","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daraxonrasib (RMC-6236) • elironrasib (RMC-6291)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-06-17"},{"id":"7356a074-029f-4a03-a916-24b6304a222f","acronym":"NST-628","url":"https://clinicaltrials.gov/study/NCT06326411","created_at":"2024-03-23T02:36:34.029Z","updated_at":"2024-07-02T16:34:59.866Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors","source_id_and_acronym":"NCT06326411 - NST-628","lead_sponsor":"Nested Therapeutics, Inc","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 04/09/2024","start_date":" 04/09/2024","primary_txt":" Primary completion: 11/01/2028","primary_completion_date":" 11/01/2028","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-05-31"},{"id":"f9c11a75-6761-45e0-ad62-a2ea23c4eb7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05379985","created_at":"2022-05-18T11:57:02.736Z","updated_at":"2024-07-02T16:35:17.915Z","phase":"Phase 1","brief_title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","source_id_and_acronym":"NCT05379985","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daraxonrasib (RMC-6236)"],"overall_status":"Recruiting","enrollment":" Enrollment 474","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-23"},{"id":"868293a8-a265-41a4-8e63-93c5f8993ec3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02704858","created_at":"2021-02-25T12:16:38.279Z","updated_at":"2024-07-02T16:35:19.174Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","source_id_and_acronym":"NCT02704858","lead_sponsor":"Neonc Technologies, Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e perillyl alcohol (NEO100)"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 04/08/2016","start_date":" 04/08/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-15"},{"id":"c588db17-efc8-49b9-af67-a28b72dc4313","acronym":"","url":"https://clinicaltrials.gov/study/NCT06096974","created_at":"2023-10-24T15:13:42.150Z","updated_at":"2024-07-02T16:35:31.995Z","phase":"Phase 1","brief_title":"Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS","source_id_and_acronym":"NCT06096974","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • HRAS mutation","tags":["PD-L1 • KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-17231"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-10-24"},{"id":"8eff224f-dd6c-4358-93e8-9182bfd305b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00837135","created_at":"2021-01-18T03:11:13.477Z","updated_at":"2024-07-02T16:37:29.739Z","phase":"Phase 1","brief_title":"GI-4000 With Adoptive Transfer in Pancreatic Cancer","source_id_and_acronym":"NCT00837135","lead_sponsor":"University of Pennsylvania","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12 • KRAS Q61L • KRAS expression","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12 • KRAS Q61L • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GI-4000"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 10/01/2009","primary_completion_date":" 10/01/2009","study_txt":" Completion: 10/01/2009","study_completion_date":" 10/01/2009","last_update_posted":"2016-08-17"}]